DE69929232D1 - Virusähnliche partikel zur induktion von autoantikörpern - Google Patents

Virusähnliche partikel zur induktion von autoantikörpern

Info

Publication number
DE69929232D1
DE69929232D1 DE69929232T DE69929232T DE69929232D1 DE 69929232 D1 DE69929232 D1 DE 69929232D1 DE 69929232 T DE69929232 T DE 69929232T DE 69929232 T DE69929232 T DE 69929232T DE 69929232 D1 DE69929232 D1 DE 69929232D1
Authority
DE
Germany
Prior art keywords
particles
virusely
autoantic
inducing
bodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929232T
Other languages
English (en)
Other versions
DE69929232T2 (de
Inventor
T Schiller
Bryce Chackerian
R Lowy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22304219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69929232(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69929232D1 publication Critical patent/DE69929232D1/de
Application granted granted Critical
Publication of DE69929232T2 publication Critical patent/DE69929232T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
DE69929232T 1998-10-21 1999-10-20 Virusähnliche partikel zur induktion von autoantikörpern Expired - Lifetime DE69929232T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10513298P 1998-10-21 1998-10-21
US105132P 1998-10-21
PCT/US1999/024548 WO2000023955A1 (en) 1998-10-21 1999-10-20 Virus-like particles for the induction of autoantibodies

Publications (2)

Publication Number Publication Date
DE69929232D1 true DE69929232D1 (de) 2006-02-02
DE69929232T2 DE69929232T2 (de) 2006-08-31

Family

ID=22304219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929232T Expired - Lifetime DE69929232T2 (de) 1998-10-21 1999-10-20 Virusähnliche partikel zur induktion von autoantikörpern

Country Status (9)

Country Link
US (5) US6719978B2 (de)
EP (1) EP1123114B1 (de)
JP (1) JP4486257B2 (de)
AT (1) ATE314095T1 (de)
AU (1) AU770802B2 (de)
CA (1) CA2347411C (de)
DE (1) DE69929232T2 (de)
ES (1) ES2258869T3 (de)
WO (1) WO2000023955A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE314095T1 (de) * 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
DE69939836D1 (de) * 1998-11-30 2008-12-11 Cytos Biotechnology Ag Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
AU2007202761B2 (en) * 2001-01-19 2010-01-21 Kuros Biosciences Ag Molecular antigen array
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
CA2492826C (en) * 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
EP1432443B1 (de) * 2001-10-05 2009-01-21 Cytos Biotechnology AG Angiotensin-träger konjugate und deren verwendung
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
PL369863A1 (en) * 2001-11-07 2005-05-02 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
MXPA04003900A (es) * 2001-11-07 2004-07-08 Cytos Biotechnology Ag Disposiciones de antigenos para el tratamiento de enfermedades oseas.
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
NZ532515A (en) * 2001-11-07 2005-10-28 Cytos Biotechnology Ag Compositions comprising a RANKL peptide attached to a core or virus-like particle for treatment of bone disease and immunization
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20040033585A1 (en) * 2002-06-07 2004-02-19 Mccormick Alison A. Flexible vaccine assembly and vaccine delivery platform
MXPA05000277A (es) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Configuraciones de antigenos moleculares de usan una particula tipo virus derivada de la proteina de recurimiento ap205.
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
EP1549140A4 (de) * 2002-09-03 2009-04-29 Kentucky Bioproc Llc Herstellung von peptiden in pflanzen als virush llproteinfusionen
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
WO2005005614A2 (en) * 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
EP1706152A2 (de) * 2004-01-20 2006-10-04 Cytos Biotechnology AG Partikelinduzierte ghrelin-immunantwort
WO2005091753A2 (en) * 2004-03-25 2005-10-06 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
WO2005117983A2 (en) * 2004-06-02 2005-12-15 Cytos Biotechnology Ag Carrier conjugates of tnf-peptides
JP2008501658A (ja) * 2004-06-02 2008-01-24 サイトス バイオテクノロジー アーゲー 非ヒトｔｎｆ−ペプチドの担体コンジュゲートの医学上の使用
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
US7959928B2 (en) 2004-10-05 2011-06-14 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
US7572451B2 (en) 2004-10-25 2009-08-11 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
EP1868642B1 (de) * 2005-03-18 2013-05-08 Cytos Biotechnology AG Katzenallergen-fusionsproteine und ihre verwendung
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
CN101193654A (zh) * 2005-06-14 2008-06-04 赛托斯生物技术公司 抗原偶联物及其用途
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP1934335A4 (de) * 2005-09-08 2010-05-05 Large Scale Biology Corp Modifizierte tabak-mosaikvirus-teilchen als gerüste zur anzeige von protein-antigenen für impfstoff-anwendungen
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
EP2125854B1 (de) 2006-12-12 2016-10-26 Kuros Biosciences AG Oligonukleotide mit hohen konzentrationen an guaninmonomeren
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
EP2012122A1 (de) * 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
WO2009009430A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Diagnosing and protecting horses against papillomavirus
EP2062592A1 (de) * 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System zur Abgabe in eine positive XCR1-Zelle und Verwendungen dafür
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
JP2013503623A (ja) 2009-09-03 2013-02-04 ファイザー バクシーンズ エルエルシー Ｐｃｓｋ９ワクチン
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
EP2755677B1 (de) * 2011-09-15 2020-11-04 Medigene AG Anti-her2-impfstoff auf der basis von multimeren strukturen aus aav
EP2948469A4 (de) 2013-01-23 2016-11-02 Univ Leland Stanford Junior Stabilisiertes hepatitis-b-kern-polypeptid
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
AU2020372478A1 (en) 2019-10-23 2022-06-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
WO2022140655A1 (en) * 2020-12-23 2022-06-30 The Trustees Of Columbia University In The City Of New York Single-molecule electronic multiplex nanopore immunoassays for biomarker detection
WO2023235410A2 (en) * 2022-06-01 2023-12-07 The Regents Of The University Of California Multivalent display of apoai peptide on nanoparticles against atherosclerosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
JPH0519914A (ja) * 1991-07-17 1993-01-29 Sharp Corp 半導体装置の内部降圧回路
KR940008286B1 (ko) * 1991-08-19 1994-09-09 삼성전자 주식회사 내부전원발생회로
CH684782A5 (de) 1992-01-27 1994-12-30 Rolf M Zinkernagel C O Inst Fu Antigen zur Auslösung von CD8+ Zellimmunantworten.
KR950008453B1 (ko) * 1992-03-31 1995-07-31 삼성전자주식회사 내부전원전압 발생회로
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5721485A (en) * 1996-01-04 1998-02-24 Ibm Corporation High performance on-chip voltage regulator designs
EP0927044A4 (de) 1996-04-16 1999-09-08 Immusol Inc Gerichtete viral vektoren
KR100224669B1 (ko) * 1996-12-10 1999-10-15 윤종용 내부 전원 전압 발생기 회로
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
JPH11231954A (ja) * 1998-02-16 1999-08-27 Mitsubishi Electric Corp 内部電源電圧発生回路
DE19827457C1 (de) 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP0994403B1 (de) * 1998-10-15 2003-05-21 Lucent Technologies Inc. Stromspiegelschaltung
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
DE69939836D1 (de) 1998-11-30 2008-12-11 Cytos Biotechnology Ag Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung
US6373754B1 (en) * 2000-07-17 2002-04-16 Samsung Electronics Co., Ltd. Semiconductor memory device having stable internal supply voltage driver
US20060210687A1 (en) * 2002-11-06 2006-09-21 Fiberstar, Inc. Enhanced crackers, chips, wafers and unleavened using highly refined cellulose fiber ingredients

Also Published As

Publication number Publication date
EP1123114B1 (de) 2005-12-28
US20040228798A1 (en) 2004-11-18
US7479280B2 (en) 2009-01-20
AU1214300A (en) 2000-05-08
JP2002528393A (ja) 2002-09-03
CA2347411A1 (en) 2000-04-27
US20080175853A1 (en) 2008-07-24
US7371572B2 (en) 2008-05-13
CA2347411C (en) 2012-04-03
JP4486257B2 (ja) 2010-06-23
DE69929232T2 (de) 2006-08-31
AU770802B2 (en) 2004-03-04
US20060210587A1 (en) 2006-09-21
EP1123114A1 (de) 2001-08-16
US20020081295A1 (en) 2002-06-27
US6719978B2 (en) 2004-04-13
WO2000023955A1 (en) 2000-04-27
ATE314095T1 (de) 2006-01-15
WO2000023955A8 (en) 2000-06-22
US7875450B2 (en) 2011-01-25
ES2258869T3 (es) 2006-09-01
US20030072753A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
EP1767544A3 (de) Methoden zur Behandlung von Entzündungskrankheiten unter Verwendung von Agentien welche spezifisch an menschliches Angiopoietin-2 binden
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
TW200510343A (en) Substituted dihydroquinazolines
HK1096392A1 (en) Substituted heterocycles
EP1492563A4 (de) Zusammensetzungen und verfahren für die diagnose und behandlung von infektionen mit dem herpes simplex virus
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
EP1303300A4 (de) Zusammensetzungen und methoden zur behandlung von candidosen
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
Koyano et al. Local factors associated with parafunction and prosthodontics.
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
EP1637166A3 (de) Virusähnliche Partikel zur Induktion von Autoantikörpern
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
AU5489500A (en) Isolation of a human retrovirus

Legal Events

Date Code Title Description
8363 Opposition against the patent